Wildtype

The salmon that surprised the FDA

On May 28, 2025, the U.S. Food and Drug Administration issued what it calls a "no questions" letter to a small San Francisco company called Wildtype. Translation: the FDA had reviewed Wildtype's cell-cultured Pacific coho salmon and concluded it was safe to sell to consumers. No caveats. No conditions. After six years of correspondence and eight rounds of amendments, the answer was simply - no questions.

It was the first time any cultivated seafood had received that clearance. The salmon now being served at omakase restaurants in Portland, San Francisco, and Austin was never a fish. It grew in a stainless steel bioreactor in the Dogpatch neighborhood of San Francisco, in roughly the same amount of time it takes to brew a batch of craft beer.

The company was founded in 2016 by two people who had no obvious business launching a seafood startup. One was a cardiologist. The other was a diplomat. Together, they decided that the best way to protect oceans was to make fishing unnecessary.

The ocean is not a warehouse

Wild salmon populations are collapsing. Atlantic salmon is no longer legally fishable in many regions due to endangered status. Pacific salmon runs are fragile. Meanwhile, global demand for seafood keeps climbing - and conventional fish farming comes with its own set of problems: antibiotic overuse, sea lice, escaped fish contaminating wild stocks, and feed inputs that often require fishing smaller fish to feed larger ones.

The product that reaches consumers - even premium, sushi-grade salmon - is rarely clean in the literal sense. Studies have found microplastics in virtually all commercially sold fish. Heavy metals accumulate through the food chain. PCBs and other persistent contaminants are standard features, not anomalies.

Wildtype's founders looked at this situation and arrived at an unfashionable conclusion: the problem isn't how we farm fish, it's that we fish at all. The only path to genuinely clean, genuinely sustainable seafood is to grow it without the ocean.

A cardiologist, a diplomat, and a bioreactor

The origin story is more unusual than most startup founders would invent. Arye Elfenbein was a cardiologist and molecular biologist at UCSF, studying how to regenerate human heart tissue using cell culture techniques. Justin Kolbeck was a former U.S. Foreign Service Officer who had been posted to Afghanistan, Pakistan, and Australia. The connection between cardiac regeneration and salmon fillets is not obvious. The connection between food insecurity in war zones and cellular agriculture is, it turns out, direct.

Kolbeck and Elfenbein started with foie gras - a controversial choice that did not survive long. They pivoted to salmon in 2017, reasoning that salmon is among the most consumed fish in the U.S., the most ecologically pressured, and the most complicated to farm cleanly. If you could solve salmon, you'd solve a large fraction of the problem.

Nine years from bioreactor to plate

Salmon, minus everything except salmon

Here is what Wildtype's product actually is. Scientists extract cells from a live Pacific coho salmon - the fish swims away unharmed. Those cells are placed into a bioreactor, a stainless steel tank that looks like brewery equipment, and fed a nutrient broth. Over four to six weeks, the cells multiply and differentiate into muscle and fat tissue. The result is combined with plant-based ingredients to form the structure of a fish fillet. The whole thing is then harvested, sliced, and served.

What it produces: buttery, melt-in-your-mouth sushi-grade salmon with rich umami flavor. What it lacks: microplastics, antibiotics, heavy metals, PCBs, sea lice, and all the other houseguests that have made conventional salmon increasingly complicated to recommend as a health food.

$123.5 million of conviction

You can tell a lot about who believes in a company by who has invested. Wildtype's investor list reads like a peculiar dinner party: a Singapore sovereign wealth fund, a major food ingredient conglomerate, the founder of Amazon, and two Hollywood actors with documented environmental commitments. That combination of capital types - strategic food industry, impact-focused, and institutional - suggests Wildtype has managed to convince skeptics across multiple categories.

The company's restaurant rollout has been equally deliberate. Rather than launching everywhere at once, Wildtype debuted at Kann in Portland - a James Beard Award-winning Haitian restaurant run by chef Gregory Gourdet. Then Robin San Francisco for omakase. Then OTOKO in Austin. The implicit argument: if serious chefs who stake their reputation on ingredient quality will serve this, it's real.

Defend wild places by making them unnecessary to exploit

Wildtype's stated mission is to defend Earth's wild places by inspiring a transition to clean and accessible seafood. That word "accessible" appears often in how the company talks about itself. It's not incidental - it's the correction to the usual critique of sustainable food products, which is that they price themselves out of the people they claim to help.

Kolbeck has said explicitly that the company will have failed its vision if cultivated salmon remains something you can only order at a $200 omakase. The Snowfox partnership - a grocery store sushi bar operator with 1,230 locations nationwide - is the mechanism for making that commitment credible. Pokéworks, with 60+ fast casual locations, is another. These are not luxury distribution channels.

The bet on the table

In 2025, the context around seafood shifted. FDA approval gave Wildtype a legitimacy that press coverage alone never could. It also put a timeline on a question the food industry has been deferring: what happens when cultivated seafood is cheaper than the alternative?

Wildtype's long-term pricing target is below farmed Atlantic salmon. Ultimately, their stated goal is sushi-grade salmon cheaper than chicken thigh. These are ambitious numbers. They require scale, cost curve improvements, and time. But they're also the only version of this story where the environmental mission actually works - where it's not a premium product for premium consumers, but just salmon.

Back in Portland, at Kann, chef Gregory Gourdet is serving cultivated salmon with pickled strawberry, spiced tomato, strawberry juice, and epis rice crackers. The diners eating it don't need to know about the FDA process or the bioreactor or the six years of regulatory correspondence. They just need to decide if it's good. So far, by the accounts of everyone who has eaten it, it is.

That's what nine years of a cardiologist and a diplomat building a brewery for fish actually looks like. Not a press release. A plate of salmon that doesn't require the ocean to still have salmon in it.

Follow, read, and try it